CGRP Receptor Antagonists for Treating Chemotherapy-Induced Nausea and Vomiting

This patent application discloses a method where gepants—CGRP receptor antagonists currently approved for migraine treatment—are used to directly treat nausea and vomiting caused by chemotherapy (CINV). The invention proposes targeting calcitonin gene-related peptide (CGRP), a neuropeptide with multiple effects in the human body, to prevent and counteract drug-induced nausea and vomiting. The application identifies antitumor chemotherapeutics as frequently causing CINV, which can compromise therapy efficacy and patient quality of life. The application was filed on September 13, 2023, under Application No. 19111786.

This publication does not create immediate compliance obligations. Pharmaceutical companies developing or manufacturing CGRP antagonists may consider whether to pursue patent protection for CINV treatment indications. Healthcare providers and patients should note this potential expanded use remains under development. The patent application does not constitute FDA approval or clearance for any specific treatment protocol.